Clinical Trials Directory

Trials / Terminated

TerminatedNCT02456675

INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma

A Phase 2, Open-Label Study of the Safety and Efficacy of INCB40093 and INCB40093 Combined With Itacitinib (INCB039110) in Subjects With Relapsed or Refractory Hodgkin Lymphoma

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
8 (actual)
Sponsor
Incyte Corporation · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

A Phase 2, open-label study to evaluate the safety and efficacy of INCB040093 as monotherapy and as combination therapy with itacitinib (INCB039110) in subjects with relapsed or refractory Hodgkin Lymphoma.

Conditions

Interventions

TypeNameDescription
DRUGINCB040093 MonotherapyINCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
DRUGINCB040093INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
DRUGitacitinibThe dose of itacitinib will be given orally once daily (QD).

Timeline

Start date
2015-06-01
Primary completion
2016-12-16
Completion
2016-12-16
First posted
2015-05-28
Last updated
2018-01-12

Source: ClinicalTrials.gov record NCT02456675. Inclusion in this directory is not an endorsement.